Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label tumor-agnostic study of MK-1084 alone or with cetuximab in advanced KRAS G12C-mutated solid tumors
MOH_2025-11-09_015448Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of calderasib and cetuximab in Nonhematologic neoplasms (2 arms), sponsored by Merck & Co. Primary endpoints: Safety of MK-1084, Efficacy of MK-1084 with or without cetuximab and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
calderasibcetuximab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2025-11-09_015448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-09_015448.